The threat from invasive meningococcal disease (IMD) remains a serious source of concern despite the licensure and availability of vaccines. A limitation of current serogroup B vaccines is the breadth of coverage afforded, resulting from the capacity for extensive variation of the meningococcus and its huge potential for the generation of further diversity.
Cross-Reactive Bactericidal Antimeningococcal Antibodies
Imperial College London
December 16, 2019
